News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Haviland Kate
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/29/2023 |
4
| Haviland Kate (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
03/08/2023 |
4
| Haviland Kate (CEO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 6,428 shares
@ $45.72, valued at
$293.9k
Sold 212 shares
@ $44.65, valued at
$9.5k
|
|
03/03/2023 |
4
| Haviland Kate (CEO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Granted 40,000 shares
@ $0 Granted 80,000 options to buy
@ $43.15, valued at
$3.5M
|
|
11/07/2022 |
4
| Haviland Kate (CEO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Bought 1,100 shares
@ $43.98, valued at
$48.4k
|
|
06/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/18/2020 |
4
| Haviland Kate (COO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 409 shares
@ $100.27, valued at
$41k
Exercised 409 options to buy
@ $36.05, valued at
$14.7k
|
|
10/20/2020 |
4
| Haviland Kate (COO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 3,009 shares
@ $102.53, valued at
$308.5k
Sold 3,125 shares
@ $101.56, valued at
$317.4k
Sold 7,200 shares
@ $100.55, valued at
$724k
Exercised 13,334 options to buy
@ $36.05, valued at
$480.7k
|
|
09/24/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/15/2020 |
4
| Haviland Kate (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns:
| Granted 9,285 options to buy
@ $17.63, valued at
$163.7k
|
|
03/11/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/14/2020 |
4
| Haviland Kate (COO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 7,763 shares
@ $85.16, valued at
$661.1k
Exercised 7,763 options to buy
@ $16.28, valued at
$126.4k
|
|
08/21/2019 |
4
| Haviland Kate (COO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 95 shares
@ $85, valued at
$8.1k
Exercised 95 options to buy
@ $16.28, valued at
$1.5k
|
|
07/18/2019 |
4
| Haviland Kate (COO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 1,222 shares
@ $95.6, valued at
$116.8k
Sold 349 shares
@ $95.03, valued at
$33.2k
Exercised 11,562 options to buy
@ $16.28, valued at
$188.2k
|
|
07/18/2019 |
4
| Haviland Kate (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.
Txns:
| Granted 9,285 options to buy
@ $16, valued at
$148.6k
|
|
07/17/2019 |
3
| Haviland Kate (Director) has filed a Form 3 on Fulcrum Therapeutics, Inc. |
06/19/2019 |
4
| Haviland Kate (COO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 933 shares
@ $100.02, valued at
$93.3k
Sold 1,000 shares
@ $98.63, valued at
$98.6k
Sold 2,123 shares
@ $97.39, valued at
$206.8k
Sold 2,977 shares
@ $96.35, valued at
$286.8k
Sold 2,549 shares
@ $95.53, valued at
$243.5k
Sold 2,370 shares
@ $94.44, valued at
$223.8k
Exercised 6,286 options to buy
@ $16.28, valued at
$102.3k
Exercised 5,666 options to buy
@ $36.05, valued at
$204.3k
|
|
03/05/2019 |
4
| Haviland Kate (COO) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 21,644 shares
@ $85.05, valued at
$1.8M
Granted 32,500 options to buy
@ $86.6, valued at
$2.8M
Granted 8,750 restricted stock units
@ $0 Exercised 14,144 options to buy
@ $16.28, valued at
$230.3k
Exercised 7,500 options to buy
@ $36.05, valued at
$270.4k
|
|
03/20/2018 |
4
| Haviland Kate (Chief Business Officer) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 500 shares
@ $102.19, valued at
$51.1k
Sold 1,800 shares
@ $101.32, valued at
$182.4k
Sold 1,200 shares
@ $100.02, valued at
$120k
Sold 571 shares
@ $99.2, valued at
$56.6k
Exercised 1,571 options to buy
@ $16.28, valued at
$25.6k
Exercised 2,500 options to buy
@ $36.05, valued at
$90.1k
|
|
03/05/2018 |
4
| Haviland Kate (Chief Business Officer) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 2,800 shares
@ $90, valued at
$252k
Exercised 2,800 options to buy
@ $36.05, valued at
$100.9k
|
|
03/01/2018 |
4
| Haviland Kate (Chief Business Officer) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 200 shares
@ $90.7, valued at
$18.1k
Sold 200 shares
@ $89.47, valued at
$17.9k
Sold 1,035 shares
@ $88.32, valued at
$91.4k
Sold 1,765 shares
@ $87.7, valued at
$154.8k
Exercised 3,200 options to buy
@ $36.05, valued at
$115.4k
|
|
02/20/2018 |
4
| Haviland Kate (Chief Business Officer) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Granted 39,000 options to buy
@ $81.44, valued at
$3.2M
|
|
02/14/2018 |
4
| Haviland Kate (Chief Business Officer) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Sold 900 shares
@ $77.19, valued at
$69.5k
Sold 2,000 shares
@ $75.64, valued at
$151.3k
Sold 2,199 shares
@ $74.58, valued at
$164k
Sold 1,476 shares
@ $73.4, valued at
$108.3k
Sold 200 shares
@ $72.64, valued at
$14.5k
Exercised 6,775 options to buy
@ $16.28, valued at
$110.3k
|
|
11/22/2017 |
4
| Haviland Kate (Chief Business Officer) has filed a Form 4 on Blueprint Medicines Corp
Txns:
| Exercised 5,874 options to buy
@ $16.28, valued at
$95.6k
|
|
10/10/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|